STOCK TITAN

Erasca COO Nicholas Chetwyn to leave November 2

Responsibilities currently overseen by the COO are transitioning to other leadership team members as Erasca streamlines its reporting structure.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

On October 15, 2026, Erasca, Inc. decided to realign leadership responsibilities to support development and potential commercialization of its RAS-targeting programs. Responsibilities currently overseen by Chief Operating Officer Nicholas (Nik) Chetwyn, Ph.D., are transitioning to other members of the leadership team to streamline the reporting structure. His employment will terminate effective November 2, 2026.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
RAS-targeting programs medical
"development and potential commercialization of its RAS-targeting programs"
commercialization technical
"potential commercialization of its RAS-targeting programs"
Commercialization is the process of bringing a new product, service, or idea to the market so that people can buy and use it. It involves turning an invention or development into something that is widely available and profitable. For investors, commercialization matters because it signals the transition from development to generating revenue, indicating potential growth and the likelihood of a return on investment.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Erasca COO Nicholas (Nik) Chetwyn leave?

Nicholas (Nik) Chetwyn, Ph.D., Erasca's Chief Operating Officer, will have his employment terminate effective November 2, 2026. His current responsibilities are transitioning to other members of the leadership team.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
false000176191800017619182026-10-152026-10-15

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2026

 

 

Erasca, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40602

83-1217027

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3115 Merryfield Row

Suite 300

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 465-6511

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

ERAS

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 15, 2026, Erasca, Inc. (the Company) decided to realign its leadership responsibilities to support the development and potential commercialization of its RAS-targeting programs. Responsibilities currently overseen by the Chief Operating Officer are transitioning to other members of the Company’s leadership team in order to streamline the Company’s reporting structure. Accordingly, the employment of Nicholas (Nik) Chetwyn, Ph.D., the Company’s Chief Operating Officer, will terminate effective November 2, 2026.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Erasca, Inc.

 

 

 

 

Date:

October 15, 2026

By:

/s/ Ebun Garner

 

 

 

Chief Legal Officer

 


Filing Exhibits & Attachments

1 document

Keep reading